Literature DB >> 15579290

Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.

Nicolai Sidenius1, Manuela Nebuloni, Stefania Sala, Pietro Zerbi, Richard W Price, Magnus Gisslen, Lars Hagberg, Luca Vago, Adriano Lazzarin, Francesco Blasi, Paola Cinque.   

Abstract

The urokinase plasminogen activator (uPA) and its receptor (uPAR) play important physiological functions in extracellular proteolysis, as well as cell adhesion and migration. Through dysregulation of these functions, the uPA/uPAR system might be involved in the pathogenesis of AIDS dementia complex (ADC), and, in fact, uPAR has been found to be overexpressed in the cerebrospinal fluid (CSF) and brain tissues of patients with ADC. On the other hand, its ligand uPA has been shown to down-regulate HIV replication in vitro. In this study, we examined uPAR and uPA expression in the brain of HIV-related lesions, as well as CSF levels of soluble uPAR (suPAR), uPA, and complexes between these two molecules (suPAR/uPA) in patients with HIV infection with or without ADC. uPAR was highly expressed by macrophages in both HIV encephalitis (HIV-E) or leukoencephalopathy (HIV-LE), with a distribution exceeding that of HIV p24 antigen. In contrast, uPA was detected only on rare cells in most of the cases. Both uPA and suPAR/uPA complex concentrations were significantly correlated with CSF suPAR levels, and CSF concentrations of both markers were higher in ADC patients than controls. However, uPA levels were substantially lower than corresponding suPAR levels. Although these findings remain correlative, they add support to the hypothesis that uPAR might be an important participant in the events leading to ADC. Additionally, these findings are consistent with a model in which overexpression of uPAR and overproduction of its soluble form may promote HIV replication via binding and removal of uPA from cell surface.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579290     DOI: 10.1016/j.jneuroim.2004.08.038

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

1.  Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression.

Authors:  Martin Hoenigl; Carlee B Moser; Nicholas Funderburg; Ronald Bosch; Amy Kantor; Yonglong Zhang; Jesper Eugen-Olsen; Malcolm Finkelman; Jochen Reiser; Alan Landay; Daniela Moisi; Michael M Lederman; Sara Gianella
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

2.  Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.

Authors:  Rick B Meeker; Winona Poulton; Silva Markovic-Plese; Colin Hall; Kevin Robertson
Journal:  J Neurovirol       Date:  2011-05-10       Impact factor: 2.643

3.  Beneficial Effects of Cannabis on Blood-Brain Barrier Function in Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Scott Peterson; Mariana Cherner; Erin Morgan; Rachel Schrier; Bin Tang; Martin Hoenigl; Scott Letendre; Jenny Iudicello
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

4.  Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients.

Authors:  Ase B Andersen; Ian Law; Karen S Krabbe; Helle Bruunsgaard; Sisse R Ostrowski; Henrik Ullum; Liselotte Højgaard; Annemette Lebech; Jan Gerstoft; Andreas Kjaer
Journal:  J Neuroinflammation       Date:  2010-02-14       Impact factor: 8.322

Review 5.  Host hindrance to HIV-1 replication in monocytes and macrophages.

Authors:  Anna Bergamaschi; Gianfranco Pancino
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

6.  Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Authors:  Massimo Alfano; Samanta A Mariani; Chiara Elia; Ruggero Pardi; Francesco Blasi; Guido Poli
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

7.  Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases.

Authors:  Manuela Nebuloni; Paola Cinque; Nicolai Sidenius; Angelita Ferri; Eleonora Lauri; Elisabetta Omodeo-Zorini; Pietro Zerbi; Luca Vago
Journal:  J Neurovirol       Date:  2008-12-24       Impact factor: 2.643

8.  Plasma (1 → 3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis.

Authors:  Sara Gianella; Scott L Letendre; Jennifer Iudicello; Donald Franklin; Thaidra Gaufin; Yonglong Zhang; Magali Porrachia; Milenka Vargas-Meneses; Ronald J Ellis; Malcolm Finkelman; Martin Hoenigl
Journal:  J Neurovirol       Date:  2019-07-11       Impact factor: 2.643

9.  Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCε.

Authors:  Francesca Graziano; Chiara Elia; Carlo Laudanna; Guido Poli; Massimo Alfano
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.